Αποτελέσματα Αναζήτησης
A non-peer reviewed report identified a 30-fold increased risk of splanchnic vein thrombosis in recipients of mRNA based vaccines such as the Comirnaty or Moderna COVID-19 vaccines (1 per 1.6 million for Vaxzevria recipients vs. 1 per 44.9 million for mRNA vaccines) . It is important to note that the report focusses on cases of CVST and ...
7 Ιουλ 2021 · Herein, we discuss the current evidence regarding pharmacological treatments, including anticoagulants, immunoglobulin therapy, steroids, and other molecules, in the management of VITT with CVST postvaccination, as well as the clinical characteristics and pathophysiology of this emerging disorder. Pathophysiology.
29 Απρ 2021 · All patients with suspected CVST due to a COVID-19 vaccine should be treated with non-heparin anticoagulants such as argatroban, bivalirudin, danaparoid, fondaparinux or a direct oral anti-coagulant (DOAC). No heparin products in any dose should be given.
Heparin is usually preferred as one of the most widely used anticoagulants for prevention and treatment of thrombotic events due to its rapid action, low cost and availability.
29 Φεβ 2024 · A diagnosis of VITT is suspected when people present with new signs and symptoms of thrombocytopenia and thrombosis within 5 to 30 days following a COVID‐19 vaccination. The most common symptoms are severe or persistent headaches, blurred vision, shortness of breath, chest pain, leg swelling, or unusual bleeding, which appear after COVID‐19 ...
12 Οκτ 2020 · With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
25 Σεπ 2021 · Non-heparin anticoagulants and immunoglobulin treatment might improve outcomes of VITT-associated cerebral venous thrombosis. Since existing criteria excluded some patients with otherwise typical VITT-associated cerebral venous thrombosis, we propose new diagnostic criteria that are more appropriate.
